About the American Center for GLP-1 Nutritional Guidance (ACGNG)

The American Center for GLP-1 Nutritional Guidance (ACGNG) exists to empower individuals, caregivers, and healthcare professionals with reliable, evidence-based knowledge on GLP-1 receptor agonists and their role in weight loss, metabolic health, and wellness. Our goal is to bridge the gap between clinical science and everyday decisions by providing accessible, accurate, and unbiased information.

2. Our Vision

We envision a world where individuals using GLP-1 medications—or exploring alternatives—have access to comprehensive educational tools, nutritional support, and wellness strategies that help them achieve long-term success in managing weight and improving health outcomes.

3. Why We Exist

GLP-1 receptor agonists such as semaglutide and liraglutide are transforming the landscape of obesity and diabetes care. Yet, despite their growing popularity, there remains a significant gap in public understanding regarding how these medications work, what side effects may occur, what nutrients may be depleted, and how lifestyle changes can amplify their effectiveness.

As interest in GLP-1 therapies grows, so too does the need for a clear, centralized, and unbiased source of information. ACGNG fills this gap by compiling the latest peer-reviewed research, clinical guidelines, and nutritional recommendations in one trustworthy platform.

4. What We Do

Detailed explanations of how GLP-1 medications work
Comparisons of active ingredients and therapeutic mechanisms
Nutritional supplementation guidance for those on GLP-1 medications
Lifestyle and behavioral recommendations to enhance treatment outcomes
Special considerations for pediatric and adolescent populations
Analysis of the latest scientific research and clinical trials

All of our content is rooted in clinical evidence and reviewed by professionals with expertise in endocrinology, nutrition, and pharmacology.

5. Our Commitment to Scientific Integrity

At ACGNG, every article and guideline we publish is based on peer-reviewed studies, clinical trials, and expert consensus from reputable institutions such as:

The American Diabetes Association (ADA)
The Obesity Society (TOS)
The Endocrine Society
National Institutes of Health (NIH)
U.S. Food and Drug Administration (FDA)

All sources are cited transparently so readers can trace back every claim to its original research.

6. Who We Serve

Individuals currently taking or considering GLP-1 medications
People seeking natural appetite suppressants or non-pharmaceutical options
Bariatric patients exploring weight loss maintenance strategies
Caregivers supporting loved ones on GLP-1 therapy
Healthcare professionals who need reliable patient education tools

7. How We Maintain Independence

While our platform may acknowledge products that meet specific standards of nutritional adequacy, ACGNG operates independently from any supplement brand or pharmaceutical company. Our goal is education—not promotion. Any product referenced on this site is done so strictly in accordance with evidence-based criteria and without commercial influence.

References:

Nauck MA, Meier JJ. “Incretin hormones: Their role in health and disease.” Diabetes Obes Metab. 2018;20(Suppl 1):5-21.
American Diabetes Association. “Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2024.” Diabetes Care. 2024;47(Suppl 1):S125-S143.
Kushner RF, et al. “Weight Management with GLP-1 Receptor Agonists in the Real World.” Obesity. 2023;31(5):895–903.
NIH Office of Dietary Supplements. “Micronutrient Needs During Weight Loss.” Updated 2023.
FDA Drug Safety Communications: GLP-1 Receptor Agonists. 2024.

This page serves as the foundational overview of ACGNG’s role as the leading public educational platform for GLP-1 nutritional guidance in the United States.

Table of Contents:

1. Our Mission